{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:24:50Z","timestamp":1751052290439},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T00:00:00Z","timestamp":1065052800000},"content-version":"vor","delay-in-days":2284,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:p> <jats:italic>Aims<\/jats:italic>\u2007Previous studies in heart failure (CHF) after temporary diuretic withdrawal have suggested that perindopril is associated with no first dose hypotension in comparison with other ACE inhibitors (ACEI) or placebo. The aim of this study was to explore further the profile of perindopril during chronic dosing.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>\u2007We report the effects of acute and chronic (8 weeks) treatment with the ACE inhibitor perindopril (Per, 2\u21924\u2003mg daily) or placebo (P) in a double\u2010blind parallel group study of 24 diuretic treated patients (17M; 67\u00b18 years, 80\u00b117\u2003kg) with ischaemic cardiomyopathy (fractional shortening, 19\u00b15%; radionuclide ejection fraction, 31\u00b13%). Baseline biochemical, hormonal (ACE, Ang I, Ang II), isotopic renal function (GFR, ERPF, ECFV), pretreatment diuretic dose and heart failure scores were similar between groups. Concomitant cardiac treatments remained unchanged and diuretic withdrawal was not used to introduce treatment.<\/jats:p><jats:p> <jats:italic>Results\u2007There were no significant effects on electrolytes, liver function tests, serum or erythrocyte magnesium. There was no significant first dose fall in SBP over 6\u2003h) (P, baseline 137\u00b118; min 115\u00b116\u2003mmHg; Per, baseline 137\u00b115; min 118\u00b117\u2003mmHg). Neither supine nor erect BP was significantly affected by chronic treatment (P, erect baseline 134\u00b123\/76\u00b110 to 124\u00b141\/74\u00b110\u2003mmHg; Per, baseline 135\u00b121\/76\u00b114 to 128\u00b122\/70\u00b112\u2003mmHg, P=NS). Active treatment was associated with significant ACE inhibition (P, baseline 47\u00b117 to 43\u00b117; Per baseline 49\u00b115 to 14\u00b17); aldosterone (P, baseline 337\u00b1179 to 375\u00b1306; Per, baseline 335\u00b1357 to 293\u00b1155\u2003pg\u2003ml<jats:sup>\u22121<\/jats:sup><\/jats:italic>\u200a) and Ang II suppression (P, baseline 9\u00b19 to 20\u00b139; Per baseline 10\u00b19 to 3\u00b13 pm\u200a). Isotopic renal function was unaffected by either treatment.<\/jats:p><jats:p> <jats:italic>Conclusions<\/jats:italic>\u2007At this dose (2\u20134\u2003mg orally) chronic perindopril therapy has no significant effect on blood pressure or renal function. Sustained neurohormonal suppression of ACE and AII occurred without evidence of AII reactivation. A lack of effect on BP at these doses may make perindopril suitable for study in unstable patients with acute HF or useful in those patients where there are concerns over ACEI induced hypotension.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1997.00618.x","type":"journal-article","created":{"date-parts":[[2003,10,14]],"date-time":"2003-10-14T19:15:11Z","timestamp":1066158911000},"page":"69-76","source":"Crossref","is-referenced-by-count":6,"title":["Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure"],"prefix":"10.1111","volume":"44","author":[{"given":"Robert J.","family":"MacFadyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel D.C.","family":"Sturrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan D.","family":"Struthers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,2]]},"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00618.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00618.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1997.00618.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T06:56:55Z","timestamp":1698389815000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1997.00618.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1046\/j.1365-2125.1997.00618.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00618.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}